Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer | Zendy

Tetsuya Sakai | Zendy; Hibiki Udagawa | Zendy; Shingo Matsumoto | Zendy; Kiyotaka Yoh | Zendy; Kaname Nosaki | Zendy; Takaya Ikeda | Zendy; Yoshitaka Zenke | Zendy; Keisuke Kirita | Zendy; Seiji Niho | Zendy; Tetsuo Akimoto | Zendy; Kōichi Goto | Zendy; Genichiro Ishii | Zendy

Open Access

Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer

Author(s) -

Tetsuya Sakai,

Hibiki Udagawa,

Shingo Matsumoto,

Kiyotaka Yoh,

Kaname Nosaki,

Takaya Ikeda,

Yoshitaka Zenke,

Keisuke Kirita,

Seiji Niho,

Tetsuo Akimoto,

Kōichi Goto,

Genichiro Ishii

Publication year - 2020

Publication title -

journal of cancer research and clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.338

H-Index - 94

eISSN - 1432-1335

pISSN - 0171-5216

DOI - 10.1007/s00432-020-03413-5

Subject(s) - pembrolizumab , adenocarcinoma , medicine , biopsy , lung cancer , oncology , cancer , hazard ratio , immunotherapy , pathology , confidence interval

The usefulness of the histopathology of biopsy samples for predicting the efficacy of immunotherapy in non-squamous, non-small cell lung cancer (NSq NSCLC) patients remains unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research